Patents by Inventor Ramzi F. Sweis

Ramzi F. Sweis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Indane inhibitors of EED and methods of their use
    Patent number: 9957274
    Abstract: Compounds having a structure of Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: May 1, 2018
    Assignee: AbbVie Inc.
    Inventors: Michael R. Michaelides, Michael L. Curtin, Huan-Qiu Li, Marina A Pliushchev, Ying Wang, Hongyu H. Zhao, Richard F. Clark, Alan S. Florjancic, Zhiqin Ji, Mariazel Torrent, Ramzi F. Sweis, Anil Vasudevan, Justin D. Dietrich
  • INDANE INHIBITORS OF EED AND METHODS OF THEIR USE
    Publication number: 20170320880
    Abstract: Compounds having a structure of Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 9, 2017
    Inventors: Michael R. Michaelides, Michael L. Curtin, Huan-Qiu Li, Marina A. Pliushchev, Ying Wang, Hongyu H. Zhao, Richard F. Clark, Alan S. Florjancic, Zhiqin Ji, Mariazel Torrent, Ramzi F. Sweis, Anil Vasudevan, Justin D. Dietrich
  • SMYD2 inhibitors
    Patent number: 9598381
    Abstract: The present disclosure generally relates to compounds having cellular anti-proliferative activities, and more particularly relates to compounds which inhibit the activity of human SMYD2, a SET and MYND domain-containing protein lysine methyltransferase.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: March 21, 2017
    Assignee: AbbVie Inc.
    Inventors: Gary G. Chiang, William N. Pappano, Ramzi F. Sweis, Zhi Wang
  • NAMPT INHIBITORS
    Publication number: 20160193209
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: March 11, 2016
    Publication date: July 7, 2016
    Applicant: AbbVie Inc.
    Inventors: Ramzi F. Sweis, Michael L. Curtin, Marina A. Pliushchev, Todd M. Hansen, Kenton Longenecker
  • NAMPT inhibitors
    Patent number: 9334264
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: May 10, 2016
    Assignee: AbbVie Inc.
    Inventors: Ramzi F. Sweis, Michael L. Curtin, Marina A. Pliushchev, Todd M. Hansen, Kenton Longenecker
  • Inhibitors of histone methyltransferase G9a
    Patent number: 9284272
    Abstract: Described herein are compounds, pharmaceutical compositions and methods for treating cancer, inflammation, or autoimmune disease in a subject, or for inhibiting histone methyltransferase G9a.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: March 15, 2016
    Assignee: AbbVie Inc.
    Inventors: Marina A. Pliushchev, Gary G. Chiang, William N. Pappano, Michael R. Michaelides, Ramzi F. Sweis
  • SMYD2 INHIBITORS
    Publication number: 20160031838
    Abstract: The present disclosure generally relates to compounds having cellular anti-proliferative activities, and more particularly relates to compounds which inhibit the activity of human SMYD2, a SET and MYND domain-containing protein lysine methyltransferase.
    Type: Application
    Filed: July 29, 2015
    Publication date: February 4, 2016
    Inventors: Gary G. Chiang, William N. Pappano, Ramzi F. Sweis, Zhi Wang
  • NAMPT inhibitors
    Patent number: 9193723
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: November 24, 2015
    Assignee: AbbVie Inc.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael R. Michaelides, Ramzi F. Sweis, Marina A. Pliushchev, Andy Judd, Todd M. Hansen, Howard R. Heyman
  • NAMPT inhibitors
    Patent number: 9187472
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: November 17, 2015
    Assignee: AbbVie Inc.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael R. Michaelides, Ramzi F. Sweis, Marina A. Pliushchev, Andy Judd, Todd M. Hansen, Howard R. Heyman
  • INHIBITORS OF HISTONE METHYLTRANSFERASE G9a
    Publication number: 20150274660
    Abstract: Described herein are compounds, pharmaceutical compositions and methods for treating cancer, inflammation, or autoimmune disease in a subject, or for inhibiting histone methyltransferase G9a.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 1, 2015
    Inventors: Marina A. Pliushchev, Gary G. Chiang, William N. Pappano, Michael R. Michaelides, Ramzi F. Sweis
  • NAMPT INHIBITORS
    Publication number: 20140336167
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: May 10, 2013
    Publication date: November 13, 2014
    Applicant: ABBVIE INC.
    Inventors: Ramzi F. Sweis, Michael L. Curtin, Marina A. Pliushchev, Todd M. Hansen, Kenton Longenecker
  • NAMPT INHIBITORS
    Publication number: 20130303511
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: May 10, 2013
    Publication date: November 14, 2013
    Applicant: AbbVie Inc.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael R. Michaelides, Ramzi F. Sweis, Marina A. Pliushchev, Andy Judd, Todd M. Hansen, Howard R. Heyman
  • NAMPT INHIBITORS
    Publication number: 20130303508
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: May 10, 2013
    Publication date: November 14, 2013
    Applicant: ABBVIE INC.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael R. Michaelides, Ramzi F. Sweis, Marina A. Pliushchev, Andy Judd, Todd M. Hansen, Howard R. Heyman
  • CETP inhibitors derived from benzoxazole arylamides
    Patent number: 8445480
    Abstract: Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease, represent a truly enormous burden to the health care systems of the industrialized world In formula I, A-B is an arylamide moiety.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: May 21, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Julianne A. Hunt, Ramzi F. Sweis, Dooseop Kim, Florida Kallashi, Peter J. Sinclair
  • CETP inhibitors derived from benzoxazole arylamides
    Patent number: 8436028
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: May 7, 2013
    Assignee: Merck Sharp & Dohme Corp
    Inventors: Julianne A. Hunt, Rogelio L. Martinez, Peter J. Sinclair, Ramzi F. Sweis
  • CETP inhibitors
    Patent number: 8334290
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: December 18, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Julianne A. Hunt, Florida Kallashi, Jennifer Kowalchick, Dooseop Kim, Cameron J. Smith, Peter J. Sinclair, Ramzi F. Sweis, Gayle E. Taylor, Christopher F. Thompson, Liya Chen, Nazia Quraishi
  • CETP inhibitors derived from benzoxazole arylamides
    Patent number: 8293721
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: October 23, 2012
    Assignee: Merck Sharpe & Dohme Corp.
    Inventors: Julianne A. Hunt, Ramzi F. Sweis, Peter J. Sinclair
  • CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES
    Publication number: 20100298288
    Abstract: Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease, represent a truly enormous burden to the health care systems of the industrialized world In formula I, A-B is an arylamide moiety
    Type: Application
    Filed: June 16, 2008
    Publication date: November 25, 2010
    Applicant: MERCK & CO., INC
    Inventors: Julianne A. HUNT, Ramzi F. Sweis, Dooseop Kim, Florida Kallashi, Peter J. Sinclair
  • CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES
    Publication number: 20100197630
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety.
    Type: Application
    Filed: June 16, 2008
    Publication date: August 5, 2010
    Inventors: Julianne A. Hunt, Rogelio L. Martinez, Peter J. Sinclair, Ramzi F. Sweis
  • CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES
    Publication number: 20100184719
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety.
    Type: Application
    Filed: June 16, 2008
    Publication date: July 22, 2010
    Inventors: Julianne A. Hunt, Ramzi F. Sweis, Peter J. Sinclair